Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations.
Marchetti M, Vannucchi AM, Griesshammer M, Harrison C, Koschmieder S, Gisslinger H, Álvarez-Larrán A, De Stefano V, Guglielmelli P, Palandri F, Passamonti F, Barosi G, Silver RT, Hehlmann R, Kiladjian JJ, Barbui T. Marchetti M, et al. Among authors: griesshammer m. Lancet Haematol. 2022 Apr;9(4):e301-e311. doi: 10.1016/S2352-3026(22)00046-1. Lancet Haematol. 2022. PMID: 35358444 Review.
Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
Michiels JJ, Kutti J, Stark P, Bazzan M, Gugliotta L, Marchioli R, Griesshammer M, van Genderen PJ, Brière J, Kiladjian JJ, Barbui T, Finazzi G, Berlin NI, Pearson TC, Green AC, Fruchtmann SM, Silver RT, Hansmann E, Wehmeier A, Lengfelder E, Landolfi R, Kvasnicka HM, Hasselbalch H, Cervantes F, Thiele J, et al. Michiels JJ, et al. Among authors: griesshammer m. Neth J Med. 1999 Feb;54(2):46-62. doi: 10.1016/s0300-2977(98)00143-0. Neth J Med. 1999. PMID: 10079679 Review.
Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET).
Barosi G, Bordessoule D, Briere J, Cervantes F, Demory JL, Dupriez B, Gisslinger H, Griesshammer M, Hasselbalch H, Kusec R, Le Bousse-Kerdiles MC, Liberato NL, Marchetti M, Reilly JT, Thiele J; European Myelofibrosis Network. Barosi G, et al. Among authors: griesshammer m. Blood. 2005 Oct 15;106(8):2849-53. doi: 10.1182/blood-2005-04-1520. Epub 2005 Jun 30. Blood. 2005. PMID: 15994287 Free article.
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.
Campbell PJ, Griesshammer M, Döhner K, Döhner H, Kusec R, Hasselbalch HC, Larsen TS, Pallisgaard N, Giraudier S, Le Bousse-Kerdilès MC, Desterke C, Guerton B, Dupriez B, Bordessoule D, Fenaux P, Kiladjian JJ, Viallard JF, Brière J, Harrison CN, Green AR, Reilly JT. Campbell PJ, et al. Among authors: griesshammer m. Blood. 2006 Mar 1;107(5):2098-100. doi: 10.1182/blood-2005-08-3395. Epub 2005 Nov 17. Blood. 2006. PMID: 16293597 Free article.
A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group.
Barosi G, Besses C, Birgegard G, Briere J, Cervantes F, Finazzi G, Gisslinger H, Griesshammer M, Gugliotta L, Harrison C, Hasselbalch H, Lengfelder E, Reilly JT, Michiels JJ, Barbui T. Barosi G, et al. Among authors: griesshammer m. Leukemia. 2007 Feb;21(2):277-80. doi: 10.1038/sj.leu.2404473. Epub 2006 Nov 16. Leukemia. 2007. PMID: 17251900
183 results